UNSPSC 51273023: Remifentanil hydrochloride

This classification denotes an opioid receptor agonist and opioid with the molecular formula C20H28N2O5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5V444H5WIC, chemically known as 4-carboxy-4-(n-phenylpropionamido)-1-piperidine propionic acid, dimethyl ester, monohydrochloride but more generally known as remifentanil hydrochloride, which bears US NIH Compound Identifier 60814.

UNSPSC 51273023 Remifentanil hydrochloride is a Commodity code that nominally describes a specific pharmaceutical agent, yet the recent state and local procurement activity tagged under it shows little alignment with that product line. Instead, the code appears in solicitations for broader pharmaceutical procurement covering generic multi-source drugs, over-the-counter products, naloxone, and direct-to-manufacturer pharmacy programs. State and local government bodies issuing under this code include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and cooperative purchasing alliances serving multiple jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and other states). The work involves sourcing pharmaceutical products through authorized wholesalers, negotiating net pricing models, and managing pharmacy benefit programs rather than procurement of remifentanil specifically.

Recent activity spans Florida, Texas, and the Upper Midwest through cooperative purchasing vehicles. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP in January 2026 (response deadline March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities, with awards effective July 1, 2026, requiring vendors to maintain relationships with AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson as authorized wholesalers and to comply with current Good Manufacturing Practices and the Drug Supply Chain Security Act. Seminole County, Florida posted an IFB in June 2026 (response deadline July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and E-Verify compliance required. The Texas HHS Commission issued an RFI in April 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription programs and direct contracting for self-insured health plans. The mismatch between the code's nominal scope and these solicitations suggests the code may be misapplied or that remifentanil procurement activity under this code is not currently visible in recent state and local posting activity.